Pfizer 2007 Annual Report Download - page 83

Download and view the complete annual report

Please find page 83 of the 2007 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 85

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85

QUARTER
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH
2006
Revenues $11,747 $11,741 $12,280 $12,603
Costs and expenses 7,178 7,877 8,070 10,060
Acquisition-related in-process research and development charges — 513 — 322
Restructuring charges and acquisition-related costs 299 268 249 507
Income from continuing operations before provision for taxes
on income, and minority interests 4,270 3,083 3,961 1,714
Provision for taxes on income 262 790 717 223
Minority interests 2 3 5 2
Income from continuing operations 4,006 2,290 3,239 1,489
Discontinued operations:
Income from discontinued operations—net of tax 102 108 120 103
Gains on sales of discontinued operations—net of tax 3 17 3 7,857
Discontinued operations—net of tax 105 125 123 7,960
Net income $ 4,111 $ 2,415 $ 3,362 $ 9,449
Earnings per common share—basic:
Income from continuing operations $ 0.55 $ 0.31 $ 0.45 $ 0.21
Discontinued operations—net of tax 0.01 0.02 0.02 1.11
Net income $ 0.56 $ 0.33 $ 0.47 $ 1.32
Earnings per common share—diluted:
Income from continuing operations $ 0.55 $ 0.31 $ 0.44 $ 0.21
Discontinued operations—net of tax 0.01 0.02 0.02 1.11
Net income $ 0.56 $ 0.33 $ 0.46 $ 1.32
Cash dividends paid per common share $ 0.24 $ 0.24 $ 0.24 $ 0.24
Stock prices
High $ 26.84 $ 25.72 $ 28.58 $ 28.60
Low $ 23.60 $ 22.51 $ 22.16 $ 23.75
Basic and diluted EPS are computed independently for each of the
periods presented. Accordingly, the sum of the quarterly EPS
amounts may not agree to the total for the year.
All financial information reflects our Consumer Healthcare business
as discontinued operations (see
Note 3. Discontinued Operations
).
Acquisition-related in-process research and development charges
primarily includes amounts incurred in connection with our
acquisitions of PowderMed and Rinat (see
Note 2. Acquisitions
).
Restructuring charges and acquisition-related costs
includes
restructuring charges primarily related to our cost-reduction
initiatives (see
Note 5. Cost-Reduction Initiatives
).
2007 Financial Report 81
Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc and Subsidiary Companies